$15.82 $0.03 (0.2%)

03:09 PM EDT on 08/04/20

Myovant Sciences Ltd. (NYSE:MYOV)

CAPS Rating: 3 out of 5

Current Price $15.82 Mkt Cap $1.4B
Open $15.81 P/E Ratio 0.00
Prev. Close $15.79 Div. (Yield) $0.00 (0.0%)
Daily Range $15.50 - $15.99 Volume 53,812
52-Wk Range $4.14 - $22.07 Avg. Daily Vol. 1,061,477

Caps

How do you think NYSE:MYOV will perform against the market?

Add Stock to CAPS Watchlist

All Players

23 Outperform
2 Underperform
 

All-Star Players

6 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NYSE:MYOV Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NYSE:MYOV VS S&P 500 (SPY)

NYSE:MYOV Summary

Fools bearish on NYSE:MYOV are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about MYOV.

Recs

0
Member Avatar ebadger33 (< 20) Submitted: 5/7/2020 9:40:57 PM : Outperform Start Price: $12.88 NYSE:MYOV Score: +9.47

this stock has seen huge insider interest in buying $11MM. Also moving over the 55 Moving Avg for quite some time. I believe it will keep moving for some time.

Recs

0
Member Avatar QueenAnneFool (43.21) Submitted: 2/7/2019 1:38:36 PM : Outperform Start Price: $18.55 NYSE:MYOV Score: -37.21

Smart leadership in a large addressable market.

Recs

0
Member Avatar dockofthebay (93.38) Submitted: 10/13/2017 2:04:46 PM : Outperform Start Price: $15.15 NYSE:MYOV Score: -25.14

Myovant Sciences has US rights to Relugolix, intended to relieve pain for woman with uterine fibroids and endometriosis, thanks to a deal with Takeda which has taken Relugolix into Phase 3 trials in Japan with some good results. Relugolix can be taken orally, which is an advantage over drugs which have to be injected to treat uterine fibroids and endometriosis. Myovant's Phase 3 trials of the drug should be complete in late 2018.

Leaderboard

Find the members with the highest scoring picks in MYOV.

Score Leader

mrkher

mrkher (< 20) Score: +161.60

The Score Leader is the player with the highest score across all their picks in MYOV.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
mrkher < 20 11/12/2019 Outperform 5Y $5.89 +168.59% +7.00% +161.60 0 Comment
Lienbuster 96.47 6/17/2019 Outperform 5Y $8.95 +76.76% +13.88% +62.88 0 Comment
PayrollGeek < 20 6/11/2019 Outperform 3Y $9.21 +71.77% +13.57% +58.20 0 Comment
mistermiranga 99.79 6/10/2019 Outperform 5Y $9.33 +69.56% +13.96% +55.60 0 Comment
chammond55 98.68 3/4/2020 Outperform 5Y $10.07 +57.10% +7.67% +49.43 0 Comment
bthym 57.06 4/16/2020 Outperform 5Y $10.77 +46.89% +18.24% +28.65 0 Comment
BigCaps18 36.74 7/13/2020 Underperform 5Y $18.50 -14.49% +3.09% +17.58 0 Comment
boomtracker 43.90 5/14/2020 Outperform 5Y $11.85 +33.50% +18.88% +14.63 0 Comment
janaynay 79.97 1/14/2020 Outperform 1Y $13.79 +14.72% +0.61% +14.11 0 Comment
cruisin25 30.01 4/24/2020 Outperform 3M $12.08 +30.96% +17.84% +13.12 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for MYOV.